Content about Ingelheim

May 16, 2013
Wireless pill bottle wins Boehringer Ingelheim-sponsored healthcare innovation contest

The makers of a pill bottle that uses wireless technology to keep patients adherent won the grand prize at a recent healthcare innovation contest.

May 2, 2013
Eli Lilly, Boehringer Ingelheim launch educational program for healthcare professionals

Drug makers Boehringer Ingelheim and Eli Lilly have started a campaign designed to educate healthcare professionals about the role a type of protein plays in maintaining blood-sugar balance.

April 5, 2013
Boehringer-Ingelheim helps sponsor Walgreens team for St. Louis colon cancer run

Boehringer-Ingelheim helped sponsor Team Walgreens/Team Tori to a tune greater than $1,000 for colon cancer research at the 2013 St. Louis Undy 5000, a family-friendly 5K run/walk created by the Colon Cancer Alliance. BI is a regular sponsor of Undy 5000 events under its Dulcolax brand.

March 25, 2013
Lilly, BI apply for diabetes drug approval

Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said.

January 30, 2013
FDA panel recommends approval for Boehringer Ingelheim COPD drug

A panel of Food and Drug Administration experts has recommended approval for an experimental drug made by Boehringer Ingelheim for chronic obstructive pulmonary disease, the drug maker said.

November 29, 2012
Laxatives for women boost category

Boehringer Ingelheim recently expanded its popular laxative brand with Dulcolax Laxative Tablets for Women, specifically formulated with a “comfort-coating” to protect a woman’s stomach. 


November 9, 2012
BI launches hepatitis C website

Drug maker Boehringer Ingelheim has created a website designed for patients with hepatitis C and advocates, the company said Friday.

October 9, 2012
Retail clinics, pharmacy take hold as health access solution

Another factor greasing the skids for health system/retail pharmacy/clinic alliances is a clear shift in cultural and societal attitudes.

September 14, 2012
Lilly, BI launch diabetes-education program

Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.

July 31, 2012
2012 Jersey Shore Undy 5000 raises more than $80,000 to help battle colon cancer

The 2012 Jersey Shore Undy 5000 raised more than $80,000 for local and national colon cancer screening, awareness and support programs, Boehringer-Ingelheim — which sponsored the event under its Dulcolax brand — announced Saturday.

July 23, 2012
Study: Long-term use of linagliptin among Type 2 diabetics is effective

Extended use of the oral DPP-4 inhibitor linagliptin to lower blood-glucose levels by Type 2 diabetes patients is effective, according to a new study.

June 21, 2012
Fighting COPD


Drug Store News recently talked with COPD Foundation founder and president John Walsh about the organization’s new leadership. In March, the COPD Foundation took over leadership for Drive4COPD, which aims to screen people for chronic obstructive pulmonary disease, a collective term for emphysema and chronic bronchitis, which the group estimates to affect 24 million Americans who may have it but don’t know it.


May 22, 2012
Boehringer Ingelheim launches Dulcolax for women

Boehringer Ingelheim last week announced the launch of Dulcolax Laxative Tablets for Women — tablets that are "comfort-coated" to protect a woman's stomach so the active ingredient, bisacodyl, is released only in the large intestine — to correspond with National Women's Health Week.

March 26, 2012
ReportersNotebook — Chain Pharmacy, 4/2/12

A drug under development by Forest Labs and Pierre Fabre has been shown to reduce symptoms of major depressive disorder, the companies said.

March 12, 2012
BI named sponsor of APhA Bowl of Hygeia Award program

One of pharmacy's top awards is getting some support from a German drug maker. Boehringer Ingelheim announced that it became a premier supporter of the American Pharmacists Association's Bowl of Hygeia Award.

March 7, 2012
Diabetes drug from Lilly, BI hits shelves

A new drug for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim is available in pharmacies, the companies said Wednesday.

February 8, 2012
BI study: No drug interaction between Aggrenox, omeprazole

An antiplatelet medication created by Boehringer Ingelheim is not affected when co-administered with a proton-pump inhibitor, according to results of a drug interaction study.

February 3, 2012
New diabetes drug launches show primary care market still strong

For all the fears about the patent cliff, at least one disease state seems to be on the up-and-up in terms of new drug development and new products.

January 31, 2012
FDA approves Lilly-Boehringer Ingelheim diabetes drug

The Food and Drug Administration has approved a new treatment for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim, the drug makers said.

January 11, 2012
Amylin outlines diabetes strategy for 2012

A special focus on its diabetes franchise will define Amylin Pharmaceuticals' corporate strategy, the company's chief executive said at a recent conference sponsored by J.P. Morgan.

December 8, 2011
Eli Lilly, Boehringer Ingelheim announce linagliptin trial results

A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

October 6, 2011
Gilead, Boehringer Ingelheim ink license agreement

Gilead Sciences has signed an agreement with Boehringer Ingelheim to gain exclusive worldwide rights to research, develop and commercialize BI's novel anti-retroviral compounds.

September 16, 2011
BI, Lilly drug reduces blood sugar over long term

A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

September 8, 2011
Boehringer Ingelheim, Eli Lilly present data from studies of diabetes drugs

Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

June 28, 2011
Study: Tradjenta reduces blood sugar, weight among patients

New data from a late-stage clinical trial of a recently approved drug for Type 2 diabetes show improved blood-sugar control in adults who take it with metformin or alone.

© 2013 Drug Store News. All Rights Reserved.